Enliven Therapeutics, Inc. (NASDAQ:ELVN) Sees Large Increase in Short Interest

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 4,640,000 shares, an increase of 9.7% from the March 31st total of 4,230,000 shares. Approximately 18.3% of the company's shares are short sold. Based on an average daily volume of 247,800 shares, the days-to-cover ratio is presently 18.7 days.

Wall Street Analysts Forecast Growth

Separately, Mizuho began coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They set a "buy" rating and a $34.00 target price on the stock.

Enliven Therapeutics Price Performance

ELVN stock traded down $0.40 during trading on Tuesday, hitting $17.39. The stock had a trading volume of 792,794 shares, compared to its average volume of 237,413. Enliven Therapeutics has a twelve month low of $9.80 and a twelve month high of $26.00. The stock has a market capitalization of $814.03 million, a P/E ratio of -8.12 and a beta of 1.06. The company's 50-day moving average price is $17.14 and its two-hundred day moving average price is $14.53.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.09. As a group, sell-side analysts expect that Enliven Therapeutics will post -2.16 EPS for the current fiscal year.

Insider Buying and Selling

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,000 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $17.56, for a total transaction of $210,720.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the firm's stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $15.00, for a total value of $7,500,000.00. Following the completion of the transaction, the insider now owns 771,983 shares in the company, valued at approximately $11,579,745. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samuel Kintz sold 12,000 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $17.56, for a total value of $210,720.00. The disclosure for this sale can be found here. Insiders have sold a total of 742,266 shares of company stock valued at $12,891,980 over the last quarter. 45.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company's stock valued at $170,000 after acquiring an additional 1,029 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Enliven Therapeutics by 17.8% in the fourth quarter. SG Americas Securities LLC now owns 13,501 shares of the company's stock valued at $187,000 after buying an additional 2,041 shares during the last quarter. AJOVista LLC purchased a new stake in shares of Enliven Therapeutics in the fourth quarter valued at about $28,000. Exchange Traded Concepts LLC raised its holdings in shares of Enliven Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company's stock valued at $121,000 after buying an additional 2,208 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company's stock valued at $140,000 after buying an additional 3,189 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.